# Vertex Pharmaceuticals Revenue

NASDAQ: VRTX · Reporting currency: USD

[Interactive page](https://beanvest.com/stock/vrtx/revenue) · [JSON with these options](https://beanvest.com/stock/vrtx/revenue.json?range=5Y&deductSbc=false&limit=200&offset=0&frequency=quarterly&wacc=7.9) · [Raw filing inputs](https://beanvest.com/api/v2/financials/vrtx)

Frequency: quarterly. Newest first. Retrieved: 2026-09-28T18:23:16.063Z.
Coverage: 2010-03-31 to 2026-06-30. Rows 1–66 of 66.
Snapshot checked: 2026-10-19T21:59:30.430Z. Last validated: 2026-11-06T22:00:21.819Z.

## Definitions

- **Total revenue** (`total_revenue`, USD_millions): Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.

## Values

| Period | End date | Total revenue (USD_millions) |
| --- | --- | --- |
| 2026-Q2 | 2026-06-30 | 3333.9 |
| 2026-Q1 | 2026-03-31 | 2986.9 |
| 2025-Q4 | 2025-12-31 | 3190 |
| 2025-Q3 | 2025-09-30 | 3076.4 |
| 2025-Q2 | 2025-06-30 | 2964.7 |
| 2025-Q1 | 2025-03-31 | 2770.2 |
| 2024-Q4 | 2024-12-31 | 2912 |
| 2024-Q3 | 2024-09-30 | 2771.9 |
| 2024-Q2 | 2024-06-30 | 2645.6 |
| 2024-Q1 | 2024-03-31 | 2690.6 |
| 2023-Q4 | 2023-12-31 | 2517.7 |
| 2023-Q3 | 2023-09-30 | 2483.5 |
| 2023-Q2 | 2023-06-30 | 2493.2 |
| 2023-Q1 | 2023-03-31 | 2374.8 |
| 2022-Q4 | 2022-12-31 | 2302.7 |
| 2022-Q3 | 2022-09-30 | 2334.3 |
| 2022-Q2 | 2022-06-30 | 2196.2 |
| 2022-Q1 | 2022-03-31 | 2097.5 |
| 2021-Q4 | 2021-12-31 | 2072.561 |
| 2021-Q3 | 2021-09-30 | 1984.164 |
| 2021-Q2 | 2021-06-30 | 1793.37 |
| 2021-Q1 | 2021-03-31 | 1724.305 |
| 2020-Q4 | 2020-12-31 | 1627.82 |
| 2020-Q3 | 2020-09-30 | 1538.271 |
| 2020-Q2 | 2020-06-30 | 1524.485 |
| 2020-Q1 | 2020-03-31 | 1515.107 |
| 2019-Q4 | 2019-12-31 | 1413.265 |
| 2019-Q3 | 2019-09-30 | 949.828 |
| 2019-Q2 | 2019-06-30 | 941.293 |
| 2019-Q1 | 2019-03-31 | 858.435 |
| 2018-Q4 | 2018-12-31 | 870.106 |
| 2018-Q3 | 2018-09-30 | 784.535 |
| 2018-Q2 | 2018-06-30 | 752.157 |
| 2018-Q1 | 2018-03-31 | 640.799 |
| 2017-Q4 | 2017-12-31 | 651.634 |
| 2017-Q3 | 2017-09-30 | 578.165 |
| 2017-Q2 | 2017-06-30 | 544.135 |
| 2017-Q1 | 2017-03-31 | 714.718 |
| 2016-Q4 | 2016-12-31 | 458.706 |
| 2016-Q3 | 2016-09-30 | 413.783 |
| 2016-Q2 | 2016-06-30 | 431.608 |
| 2016-Q1 | 2016-03-31 | 398.08 |
| 2015-Q4 | 2015-12-31 | 417.935 |
| 2015-Q3 | 2015-09-30 | 309.816 |
| 2015-Q2 | 2015-06-30 | 166.076 |
| 2015-Q1 | 2015-03-31 | 138.509 |
| 2014-Q4 | 2014-12-31 | 144.556 |
| 2014-Q3 | 2014-09-30 | 178.987 |
| 2014-Q2 | 2014-06-30 | 138.421 |
| 2014-Q1 | 2014-03-31 | 118.451 |
| 2013-Q4 | 2013-12-31 | 351.157 |
| 2013-Q3 | 2013-09-30 | 221.7 |
| 2013-Q2 | 2013-06-30 | 310.75 |
| 2013-Q1 | 2013-03-31 | 328.368 |
| 2012-Q4 | 2012-12-31 | 333.994 |
| 2012-Q3 | 2012-09-30 | 336.006 |
| 2012-Q2 | 2012-06-30 | 418.305 |
| 2012-Q1 | 2012-03-31 | 438.737 |
| 2011-Q4 | 2011-12-31 | 563.34 |
| 2011-Q3 | 2011-09-30 | 659.2 |
| 2011-Q2 | 2011-06-30 | 114.424 |
| 2011-Q1 | 2011-03-31 | 73.662 |
| 2010-Q4 | 2010-12-31 | 65.524 |
| 2010-Q3 | 2010-09-30 | 23.795 |
| 2010-Q2 | 2010-06-30 | 31.622 |
| 2010-Q1 | 2010-03-31 | 22.429 |

## Business drivers

Reviewed 2026-10-20T12:04:57.909Z. Independent reported series; these are not assumed to form an additive breakdown.

### TRIKAFTA/KAFTRIO revenue

Reported quarterly TRIKAFTA/KAFTRIO revenue. Unit: iso4217:USD. Cadence: quarterly.

| From | Through | Reported value | Source |
| --- | --- | --- | --- |
| 2025-01-01 | 2025-03-31 | 2535500000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2025-04-01 | 2025-06-30 | 2551100000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |
| 2026-01-01 | 2026-03-31 | 2354700000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2026-04-01 | 2026-06-30 | 2497200000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |

### ALYFTREK revenue

Reported quarterly ALYFTREK revenue. Unit: iso4217:USD. Cadence: quarterly.

| From | Through | Reported value | Source |
| --- | --- | --- | --- |
| 2025-01-01 | 2025-03-31 | 53900000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2025-04-01 | 2025-06-30 | 156800000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |
| 2026-01-01 | 2026-03-31 | 424400000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2026-04-01 | 2026-06-30 | 573600000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |

### CASGEVY revenue

Reported quarterly CASGEVY revenue. Unit: iso4217:USD. Cadence: quarterly.

| From | Through | Reported value | Source |
| --- | --- | --- | --- |
| 2025-01-01 | 2025-03-31 | 14200000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2025-04-01 | 2025-06-30 | 30400000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |
| 2026-01-01 | 2026-03-31 | 42900000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2026-04-01 | 2026-06-30 | 76400000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |

### JOURNAVX revenue

Reported quarterly JOURNAVX revenue. Unit: iso4217:USD. Cadence: quarterly.

| From | Through | Reported value | Source |
| --- | --- | --- | --- |
| 2025-01-01 | 2025-03-31 | 1300000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2025-04-01 | 2025-06-30 | 12000000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |
| 2026-01-01 | 2026-03-31 | 29000000 | [Report filed 2026-05-05](https://www.sec.gov/Archives/edgar/data/875320/000087532026000173/vrtx-20260331.htm) |
| 2026-04-01 | 2026-06-30 | 49600000 | [Report filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm) |

Reporting limitations:
- Reported observations cover only part of each year and measure revenue rather than patient adoption or treatment volume.

## Business disclosures

Reviewed 2026-10-20T20:45:17.900Z. Original dated quotations; initiatives and plans do not establish delivered results.

### Cystic Fibrosis (CF) Portfolio

Disclosure type: operating disclosure.

> 2
> Key Business Highlights
> Marketed Products 
> Cystic Fibrosis (CF) Portfolio
> Vertex has worked for more than 20 years to discover and develop medicines to treat the underlying cause of CF.

[Original disclosure 2026-08-03](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)

### VX-670

Disclosure type: initiative.

> •Vertex recently completed enrollment and continues to dose people with DM1 in the multiple ascending dose portion of the GALILEO global Phase 1/2 clinical trial of VX-670.

[Original disclosure 2026-08-03](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)

## Sources

- [sec-0000875320-3f73be48f927](https://data.sec.gov/api/xbrl/companyfacts/CIK0000875320.json) · Retrieved 2026-09-28T07:37:41.538Z · SHA-256 3f73be48f9279b6b1c07339b9c5ea0e2a7f5d757cd6f8c4015e141ec7ed8e4b8
- [inline-0000875320-42237d5c489b](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm) · Retrieved 2026-10-17T22:57:24.793Z · SHA-256 42237d5c489bd2b22fadb861571372eb6f4d591855e862139dfcb7e75f39d672
- [inline-0000875320-e4dece7e24f8](https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/vrtx-20231231.htm) · Retrieved 2026-10-18T12:24:07.058Z · SHA-256 e4dece7e24f8d0c8c2da4354a8aaf316389fc015d684486ddededcf9e0cde8dd

## Data conventions

- Null means an unavailable input or undefined calculation, never zero. Values are unrounded; money and shares are in millions unless a column states otherwise.
- Fiscal periods use actual reporting start/end dates. Annual reported values are not constructed by adding quarterly EPS or weighted share counts. Partial years are labelled.
- FCF uses operating cash flow minus reported cash capital investment, preferring PPE purchases. The productive-assets fallback can also include software and intangibles. Acquisitions and noncash leases are excluded. Deduct SBC is an optional economic-cost scenario; missing SBC remains unavailable.
- SBC / FCF and SBC / OCF compare amounts from the same fiscal period. SBC / FCF always uses FCF before SBC deduction; nonpositive denominators are undefined and values above 100% remain valid.
- Capital allocation percentages describe available tracked cash uses, not all company spending or a fraction of OCF. Missing categories remain null, negative payments are excluded and SBC is noncash. Annual shares use reported annual amounts.
- Valuation uses completed, split-adjusted closes without dividend adjustment and a complete trailing year. Financial bases become eligible after publication; selected facts can contain later restatements. This is not a vintage-filings backtest.
- Mean and median use all valid observations in the selected date range before pagination. Historical pricing labels compare the latest positive value with its own median and do not estimate intrinsic fair value.
- Reporting currencies are retained without conversion. USD market capitalization, where available, is a separate dated Nasdaq snapshot.
- WACC is an editable US industry scenario across history, not a historical company cost of capital. Industry exclusions, missing inputs and pending filings remain explicit.
